美女免费一级视频在线观看

Global life sciences and commercialization partner for pharma firm Inizio has a new captain to steer the ship. The firm announced on Tuesday that longtime chief operating officer Ryan Quigley will be succeeding Paul Taaffe as CEO of the global company.

Quigley has over two decades of experience working for big pharmaceutical brands like Abbott, Zeneca and AbbVie, working in senior leadership roles where he was responsible for launching blockbuster brands across major markets. He then stepped into the agency world, working with UDG Healthcare before transitioning into Inizio.

As CEO, he will be responsible for leading the company, which does $1.6 billion in revenue with more than 10,500 employees worldwide. He will also work closely with leaders of the five connected business units, which include Medical, Advisory, Evoke, Engage and Biotech.

Taaffe will stay on as a board member of the company.

“I’m delighted Paul is going to actually stay with the company. Paul has been an active board member for us, and will sustain and remain on the board at Inizio, helping us to really unlock that next wave of growth overall,” said Quigley.

“We’ve got an absolutely fantastic team, and we’ve also got a beautiful blend of people,” added Quigley when touching on the team he will continue to be working with in his new role.

Quigley noted the firm’s long standing expertise in the oncology, GLP-1 and immunology spaces, working alongside big pharma clients alongside their drug development.

“The primary part of our work is probably in that two to three years pre-launch, and in that growth phase of where our clients really accelerate the launches,” said Quigley. “I don’t think anybody else in the market has that fully connected suite of capabilities to be able to use, not just in marketing, but in medical to advisory to full engagement services.”

He also noted that the team is doubling down on its data and AI capabilities, particularly when it comes to delivering better insights.

“When a client today is launching a new asset into the market, we will go out and we’ll look at their brand strategy at a global level, their brand strategy in affiliate markets, like in the US market. Our capabilities stretch right across the product life cycle such as we do an in-person audit of the sales rep in the field to see how the message is really getting across to those physicians,” said Quigley, touching on the traditional approach to engaging HCPs.

“Today, we’re in the process of bringing a new tool to the market, which is actually able to record in real time those conversations in the field, and actually shorten that journey from eight to 12 weeks to a couple of weeks,” he added.

When it comes to oncology, Quigley said that Inizio is one of the biggest partners. Over the course of the week at the 2025 ASCO Annual Meeting, Inizio supported more than 30 clients.

“Today, we probably have supported clients launching assets into about 80% plus of the approved indications in oncology,” said Quigley.

Quigley also said that Inizio has interest in participating in the GLP-1 space, noting how the team is working to make treatments more accessible for patients.

“It’s not just about diabetes. It’s about us being able to connect, for companies that have really good experience today in the diabetes and obesity with neuroscience indications. It’s about being able to take them into different areas,” said Quigley.